China's mRNA tumor vaccine approved for clinical trials
China DailyBEIJING - A new injection, which is an mRNA vaccine for Epstein-Barr virus positive tumors, has been approved by the Center for Drug Evaluation of the National Medical Products Administration for Phase-I clinical trials. The new injection, independently developed by WestGene Biopharma Co., Ltd. in Chengdu, Southwest China's Sichuan province, received the Investigational New Drug approval from the US Food and Drug Administration in May this year and has completed the Investigator-Initiated Trials in two indications including nasopharyngeal carcinoma and lymphoma. And mRNA tumor therapeutic vaccine is one of the major breakthroughs in the field of mRNA innovative drugs and tumor immunotherapy. The company will conduct more clinical trials across the country to promote the application of the mRNA vaccine as soon as possible.
History of this topic
What is the cancer vaccine Russia is offering? | Explained
The Hindu
Beyond COVID-19 vaccines: what else could mRNA technology do for our health?
The Hindu
China’s bet on homegrown mRNA vaccines holds back nation
Associated Press
China's bet on homegrown mRNA vaccines holds back nation
The Independent
China’s insistence on a homegrown mRNA vaccine haunts its COVID-control efforts
LA Times
Will there be an mRNA vaccine for cancer?
The Hindu
Scientist behind coronavirus shot says next target is cancer
The Independent
Scientist behind coronavirus shot says next target is cancer
Associated PressDiscover Related